On December 12, 2025, Milestone Pharmaceuticals Inc. announced that the FDA approved their new drug application for CARDAMYST (etripamil) nasal spray, aimed at managing paroxysmal supraventricular tachycardia (PSVT). This is a significant event for the company, with a positive sentiment from an investor perspective.